Influence of nonalcoholic fatty liver disease on the therapeutic effect of nucleoside (acid) analogs for hepatitis B virus

Table 3 Baseline demographic data and clinical features of high viral load chronic hepatitis B combined with nonalcoholic fatty liver disease, n (%)/mean ± SD

Characteristics	NAFLD	Non-NAFLD	t/χ2	P value
	(n = 40)	(n = 80)
Gender			χ2 = 8.450	0.004
Male	37 (92.5)	53 (66.3)
Female	3 (7.5)	27 (33.7)
Age (years)	29.5 ± 5.6	31.0 ± 7.1	t = 1.161	0.2480
HBV DNA baseline level, log10 (IU/mL)	8.1 ± 0.5	8.0 ± 0.5	t = 0.3877	0.6990
Virus shedding time (months)	16.8 ± 6.1	13.0 ± 6.8	t = 3.003	0.0033
Virology breakthrough time (months)	6.8 ± 5.6	10.9 ± 11.5	t = 1.378	0.1735
HBsAg baseline level, log10 (IU/mL)	4.4 ± 0.6	4.2 ± 0.7	t = 1.252	0.2148
Antiviral therapy			t = 1.985	0.371
ETV	4 (10.0)	15 (18.8)	t = 1.532	0.216
TDF	12 (30.0)	26 (32.5)	t = 0.077	0.781
ETV and TDF	24 (60.0)	39 (48.7)	t = 1.353	0.245
low-level viremia	30 (75.0)	49 (61.3)	t = 2.241	0.134
Virological response			χ2 = 8.750	0.003
Complete virologic response	5 (12.5)	31 (38.8)
Partial virologic response	35 (87.5)	49 (61.2)
Serological response (HBsAg)			χ2 = 0.0000	1.000
Yes	1 (2.5)	2 (2.5)
No	39 (97.5)	78 (97.5)
Serological response (HBeAg)			χ2 = 3.116	0.078
Yes	1 (2.5)	12 (15.0)
No	39 (97.5)	68 (85.0)
Leucocytes, (G/L)	6.4 ± 2.1	5.5 ± 1.6	t = 2.414	0.0175
Erythrocyte, (T/L)	5.2 ± 0.4	4.9 ± 0.5	t = 3.308	0.0013
Platelets, (G/L)	228.5 ± 51.2	200.4 ± 54.2	t = 2.489	0.0144
Haemoglobin, (G/L)	155.4 ± 16.6	146.5 ± 16.7	t = 2.533	0.0128
Neutrophils, (G/L)	3.8 ± 1.8	3.1 ± 1.3	t = 2.232	0.0278
Lymphocytes, (G/L)	2.0 ± 0.5	1.9 ± 0.5	t = 1.277	0.2043
Total bilirubin, log10 (μmol/L)	1.2 ± 0.2	1.2 ± 0.2	t = 0.2773	0.7820
≤ 19	29 (72.5)	54 (67.5)	t = 0.313	0.576
> 19	11 (27.5)	26 (32.5)
Alanine aminotransferase, log10 (U/L)	1.7 ± 0.3	1.9 ± 0.5	t = 1.814	0.0722
≤ 35	6 (15.0)	17 (21.3)	t = 0.672	0.412
> 35	34 (85.0)	63 (78.7)
Aspartate aminotransferase, log10 (U/L)	1.5 ± 0.2	1.7 ± 0.4	t = 2.545	0.0122
≤ 40	21 (52.5)	29 (36.3)	t = 2.897	0.089
> 40	19 (47.5)	51 (63.7)
APRI score	0.5 ± 0.4	0.8 ± 0.6	t = 2.639	0.0096
Fibrosis-4 score	0.7 ± 0.4	1.0 ± 0.6	t = 2.631	0.0098
Total protein, (g/L)	75.6 ± 5.8	74.3 ± 5.1	t = 1.336	0.1841
Albumin, (g/L)	45.7 ± 2.4	43.7 ± 3.4	t = 3.414	0.0009
Globulin, (g/L)	29.9 ± 5.2	30.6 ± 4.3	t = 0.7613	0.4480
Urea nitrogen, (mmol/L)	4.6 ± 1.3	4.2 ± 1.2	t = 1.599	0.1125
Creatinine, (μmol/L)	76.3 ± 7.5	71.1 ± 11.2	t = 2.542	0.0124
Uric acid, (μmol/L)	413.7 ± 95.7	314.0 ± 86.8	t = 5.546	< 0.0001
Fasting glucose, (mmol/L)	5.3 ± 0.5	5.8 ± 2.4	t = 0.8360	0.4074
Triglyceride, (mmol/L)	1.6 ± 1.6	1.0 ± 0.5	t = 2.085	0.0418
Total cholesterol, (mmol/L)	4.5 ± 0.8	4.2 ± 0.9	t = 1.328	0.1897
High-density lipoprotein, (mmol/L)	1.0 ± 0.2	1.2 ± 0.3	t = 1.886	0.0647
Low-density lipoprotein, (mmol/L)	2.9 ± 0.7	2.5 ± 0.8	t = 1.768	0.0827
Treatment follow-up period, (months)	33.8 ± 16.8	35.1 ± 17.8	t = 0.3550	0.7233

NAFLD: Nonalcoholic fatty liver disease; ETV: Entecavir; TDF: Tenofovir disoproxil fumarate; HBV DNA: Hepatitis B virus deoxyribonucleic acid; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen; APRI: Aspartate aminotransferase-to-platelet ratio index.